These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 32473921)
1. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research. Frigerio M Int J Cardiol; 2020 Oct; 316():285-286. PubMed ID: 32473921 [No Abstract] [Full Text] [Related]
2. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend. Hor CP; Hussin N; Nalliah S; Ooi WT; Tang XY; Zachariah S; Jugindar Singh GPS; Abdul Rani R; Perumal K; Cheah WK J Infect; 2020 Aug; 81(2):e117-e119. PubMed ID: 32474031 [No Abstract] [Full Text] [Related]
4. Hydroxychloroquine and azithromycin as a treatment of COVID-19. Fanin A; Calegari J; Beverina A; Tiraboschi S; Intern Emerg Med; 2020 Aug; 15(5):841-843. PubMed ID: 32474851 [No Abstract] [Full Text] [Related]
5. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous? Popescu CP; Fischer PR Travel Med Infect Dis; 2020; 35():101764. PubMed ID: 32485391 [No Abstract] [Full Text] [Related]
6. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France". Lebeaux D; Revest M Travel Med Infect Dis; 2020; 36():101819. PubMed ID: 32629139 [No Abstract] [Full Text] [Related]
7. Flexibilization of Science, Cognitive Biases, and the COVID-19 Pandemic. Oliveira J E Silva L; Vidor MV; Zarpellon de Araújo V; Bellolio F Mayo Clin Proc; 2020 Sep; 95(9):1842-1844. PubMed ID: 32861327 [No Abstract] [Full Text] [Related]
8. Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going. Parra-Lara LG; Martínez-Arboleda JJ; Rosso F J Glob Antimicrob Resist; 2020 Sep; 22():680-684. PubMed ID: 32622008 [TBL] [Abstract][Full Text] [Related]
9. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. Funck-Brentano C; Salem JE; Nguyen LS; Drici MD; Roden DM Arch Cardiovasc Dis; 2020 May; 113(5):367-368. PubMed ID: 32331979 [No Abstract] [Full Text] [Related]
10. Deploying Randomized Controlled Trials during the COVID-19 Pandemic: Reason and Bayesian Designs. Zampieri FG Ann Am Thorac Soc; 2020 Aug; 17(8):937-938. PubMed ID: 32735169 [No Abstract] [Full Text] [Related]
11. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19. Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906 [No Abstract] [Full Text] [Related]
12. Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center. Pothen L; Yildiz H; De Greef J; Penaloza A; Beauloye C; Belkhir L; Yombi JC Travel Med Infect Dis; 2020; 36():101788. PubMed ID: 32540396 [No Abstract] [Full Text] [Related]
13. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France". Bonny A; Talle MA; Ngantcha M; Tayebjee MH Travel Med Infect Dis; 2020; 37():101861. PubMed ID: 32889105 [No Abstract] [Full Text] [Related]
14. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. Rosendaal FR Int J Antimicrob Agents; 2020 Jul; 56(1):106063. PubMed ID: 32674928 [No Abstract] [Full Text] [Related]
15. [Not Available]. Farfán-López M; Espinoza-Culupú A Rev Peru Med Exp Salud Publica; 2020; 37(2):383-384. PubMed ID: 32876237 [No Abstract] [Full Text] [Related]
16. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. Bessière F; Roccia H; Delinière A; Charrière R; Chevalier P; Argaud L; Cour M JAMA Cardiol; 2020 Sep; 5(9):1067-1069. PubMed ID: 32936266 [TBL] [Abstract][Full Text] [Related]
17. Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19". Atkinson JG Int J Infect Dis; 2020 Oct; 99():37. PubMed ID: 32738492 [No Abstract] [Full Text] [Related]
18. The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials. Malviya A Int J Infect Dis; 2020 Oct; 99():310-311. PubMed ID: 32738490 [No Abstract] [Full Text] [Related]
19. Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA). Dar SA; Wahid M; Haque S; Almalki SS; Akhter N Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):7923-7924. PubMed ID: 32767316 [No Abstract] [Full Text] [Related]
20. RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS". Peiffer-Smadja N; Costagliola D Am J Epidemiol; 2020 Nov; 189(11):1443-1444. PubMed ID: 32685975 [No Abstract] [Full Text] [Related] [Next] [New Search]